Research Article
ATAD2 Overexpression Identifies Colorectal Cancer Patients with Poor Prognosis and Drives Proliferation of Cancer Cells
Table 1
Relationship between ATAD2 expression and clinicopathological features in 300 colorectal cancer patients.
| | Variable | ATAD () | | Low | High | | | |
| | Age | | | | | ≤65 years | 73 (24.33) | 97 (32.33) | 0.518 | | >65 years | 51 (17.00) | 79 (26.34) | | Gender | | | | | Male | 68 (22.37) | 99 (32.57) | 0.978 | | Female | 56 (18.42) | 81 (26.64) | | Tumor size | | | | | ≤5 cm | 78 (26.00) | 72 (24.00) | <0.001 | | >5 cm | 46 (15.33) | 104 (34.67) | | Tumor location | | | | | Rectum | 73 (24.33) | 103 (34.33) | 0.873 | | Colon | 51 (17.01) | 73 (24.33) | | Serum CEA | | | | | ≤5 ng/mL | 74 (24.67) | 79 (26.33) | 0.012 | | >5 ng/mL | 50 (16.67) | 97 (32.33) | | Lymph node metastasis | | | | | N0 | 53 (17.67) | 52 (17.33) | 0.018 | | N1-N2 | 71 (23.67) | 124 (41.33) | | Liver metastasis | | | | | M0 | 109 (36.33) | 137 (45.66) | 0.025 | | M1 | 15 (5.00) | 39 (13.00) | | Clinical stage | | | | | I | 17 (5.67) | 12 (4.00) | 0.004 | | II | 23 (7.67) | 16 (5.33) | | III | 69 (23.00) | 109 (36.33) | | IV | 15 (5.00) | 39 (13.00) |
|
|
